So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific ...

With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to ...

When it comes to pre-revenue biotechs, it's often a struggle to build an investment thesis beyond "if the medicine works, the ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

Its lead candidate, VK2735, will start its phase 3 clinical trials soon after the company meets with regulators at the Food and Drug Administration to discuss a few details; assuming standard ...

VK2735 is being tested in two formulations: one that's a weekly injection, and one that's a daily pill. The pill form is expected to start its phase 2 clinical trials before the end of this year ...

The company reported its dual GLP-1/GIP co-agonist drug VK2735 saw up to an average of 8.2% weight loss over 28 days on its highest-tested dose of 100 mg.

Viking Therapeutics (VKTX) is up more than +5% after the company’s experimental pill, VK2735, showed weight loss in patients at higher doses with limited side effects. Air Transport Services Group ...